Company intelligence / Profile preview

MiNK Therapeutics

New York, New York, United Statesminktherapeutics.com ↗

Ownership: Public · INKT
Employees: ~23
Development stage: Other

Overview

Currently in Phase 2 clinical trial for the combination of agenT-797, botensilimab plus balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastro-esophageal junction adenocarcinoma. Also in Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors for refractory solid tumor cancers, and Phase 1 trial for viral acute respiratory distress syndrome.

Therapeutic areas: OncologyPulmonologyImmunology
Modalities: Allogeneic invariant natural killer T (iNKT) cell therapiesCAR-iNKTTCR therapies
Industry: Biotech

Drug pipeline

12 assets

agenT-797

11 more assets in the full pipeline.

Partnerships

Autonomous TherapeuticsImmunoScape, Inc.

Financials

Market cap: $51.3M
Total revenue: $0
Enterprise value: $42.5M

Beyond the preview

Go deeper on MiNK Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MiNK Therapeutics.